

# Index

## A

Acute GVHD (aGVHD)  
  allo-SCT modalities, 78  
  ASBMT, 83  
  cytokine milieu, 80  
  DCR, 83  
  donor T-cells, 77  
  FCS, 81  
  grading and scoring, 78  
  human autologous serum, 81  
  MMF/sirolimus, 78  
  MSC therapy, 79  
  potency assay/markers, 84  
  Prochymal™, 81  
  steroid-refractory, 80, 81  
  strategy, 78, 82  
  systematic review and meta-analysis, 80  
  target organs, 78  
  treatment, 78  
Acute kidney injury (AKI), 113, 114  
Adaptive immunity, 66, 67  
Addison's disease, 4  
Adipose stem cells (ASCs), 57  
Adipose tissue MSC (Ad-MSC), 70, 71  
Adjuvant-induced arthritis, 7  
Allogeneic hematopoietic stem cell transplantation (allo-SCT)  
  curative approach, 77  
  steroid-refractory, 80  
  transplantation setting, 79  
  treatment, 80  
Allogenic use, 67, 68  
Alveolar-arterial oxygen gradient (A-aDO<sub>2</sub>), 148  
Alzheimer's disease, 143

5-Aminosalicylic acid (5-ASA), 126  
Amniotic membrane, 11  
Amyotrophic lateral sclerosis (ALS), 12, 45, 114  
Antibiotics, 126  
Antigen presenting cells (APCs), 29, 141  
Anti-inflammatory cytokines, 132  
AT-derived MSCs (AT-MSCs), 129  
Atherosclerosis, 143  
Autoimmune diseases (AD)  
  ailments, 39  
  autoimmunity (*see* Autoimmunity)  
  cellular and molecular components, 28  
  hUC-MSC-EVs, 38, 39  
  immunosuppressive drugs, 28  
  MSCs, 37, 38  
Autoimmune diseases working party (ADWP), 8  
Autoimmune hemolytic anemia, 4  
Autoimmunity  
  cellular mechanism, 29, 30  
  molecular mechanism, 30, 31  
  MSCs, 31, 32  
Autologous Blood and Marrow Transplant Registry Database (ABMTR) registries, 10  
Autologous Stem Cell Transplantation International Scleroderma Trial (ASTIS), 8  
Azathioprine, 4

## B

Banked umbilical cord blood, 11  
Belimumab, 14

- Biostatistical analysis  
 fisher test, 94  
 functional enrichment analysis, 94  
 GO-tree, 93  
 KEGG, 93, 94  
 NFκB signaling, 94, 98  
 pathways and functional components, 93  
 PI3K-Akt and MAPK signaling  
 pathways, 94  
 Reactome pathways, 94, 98
- Blood-brain barrier, 48, 53
- Bone marrow derived MSCs  
 (BM-MSCs), 67, 68
- C**
- Cardiomyocytes, 5
- Cell adhesion molecule (CAM), 69
- Cell-based MSC therapies  
 anti-inflammatory drugs/nanoparticles, 89  
 nerve cell therapy, 112  
 neurodegenerative diseases, 114  
 prognostic biomarkers, 90  
 stroke injury, 113
- Center for International Blood and Marrow  
 Transplant Research (CIBMTR)  
 registry, 10
- Central nervous system (CNS), 45
- Chronic GVHD (cGVHD)  
 autologous serum, 84  
 first-line therapy, 84  
 NIH consensus documents, 84  
 pathophysiology, 78  
 therapeutic approaches, 79  
 trials, 84
- Chronic kidney disease (CKD), 115
- Chronic obstructive pulmonary disease  
 (COPD)  
 aging individuals, 140  
 chronic bronchitis and emphysema, 139, 140  
 cigarette smoke, 139  
 healthcare, 139  
 inflammation, 140, 141, 143, 144  
 long-term studies, 150  
 lung diseases, 149, 150  
 MSC, 147, 148  
 senescence, 141–144, 150  
 senolytic drugs, 146, 147  
 side effects, 145, 146  
 symptoms, 139  
 treatment, 144, 145, 148, 149
- Colony-forming units (CFUs), 6
- Complete response rate (CRR), 81
- Corticosteroids, 4, 17
- Crohn's disease (CD), 8, 12, 13, 15, 16
- IBD (*see* Inflammatory bowel diseases  
 (IBDs))
- Crohn's disease activity index (CDAI), 129
- Cyclophosphamide (CYC), 4, 7–9, 11, 12
- D**
- Dendritic cells (DCs), 30, 31, 38, 66, 126, 140
- Disease activity score 28 (DAS28), 68, 69
- DNA damage response (DDR), 142
- Durable complete response (DCR), 83
- E**
- Efficacy, 46, 50, 51
- Embryonic stem cells (ESCs), 29, 46
- Epidermal growth factor (EGF), 127
- Epidermal nerve stem cells (EPI-NCSCs), 49
- Epithelial-mesenchymal transition (EMT), 142
- Estimated glomerular filtration rates  
 (eGFR), 115
- European Society for Blood and Marrow  
 Transplantation (EBMT)  
 registry, 10
- F**
- Fetal calf serum (FCS), 81
- G**
- Gene-ontology (GO), 93
- Global Initiative for Chronic Obstructive Lung  
 Disease (GOLD), 139
- Glomerulonephritis, 4
- Goodpasture's syndrome, 4
- Graft-versus-host disease (GVHD)  
 aGVHD, 80–84  
 cGVHD, 84–85
- Granulocyte-colony stimulating factor  
 (G-CSF), 7
- Graves' disease, 4
- H**
- Hashimoto's thyroiditis, 4
- Hematopoietic stem cells (HSCs), 55, 56  
 in vivo, 6  
 mice and humans, 6  
 sources, 6, 7
- Hematopoietic stem cell transplantation  
 (HSCT)  
 AD treatment, 10, 11  
 autoimmune diseases, 7, 8  
 blood cells, 6

in vitro, 6  
 RA, 9, 10  
 SLE, 9  
 sources, 7  
 spleen and bone marrow, 6  
 SSc, 8, 9  
 Hepatocyte growth factor (HGF), 37, 127  
 Human mesenchymal uterine cervical stem  
 cells (hUCESCs), 93  
 Human umbilical vein epithelial cells  
 (HUVEC), 143, 146, 147  
 Hypocomplementemia, 14

## I

Idiopathic thrombocytopenia, 4  
 IL-1 receptor antagonist (IL-1RA), 64, 66  
 Immune-modulatory  
   IDO, 91  
   MLR, 115  
   therapeutic application, 116  
   treatment, 89  
 Immunomodulatory drugs, 126  
 Immunosuppressive cytokines, 130  
 Indoleamine 2,3-dioxygenase (IDO), 37–39  
 Induced pluripotent stem cells (iPSC), 29  
 Inflammatory bowel diseases (IBDs)  
   activated M1 macrophage, 126  
   antibiotics and 5-ASA, 126  
   application  
     anti-MHC class I antibodies, 131  
     AT-MSCs, 130  
     autologous MSCs, 130  
     BM-MSCs, 128–130  
     clinical trials, 128, 131  
     perianal fistulas, 128  
     single intrafistular transplantation, 130  
   challenges, 133, 134  
   cigarette smoking, 125  
   etiology, 125  
   family background, 125  
   molecular mechanisms, 127  
   MSCs, 126  
   pathogenesis, 125  
   pathologic changes, UC patients, 126  
   therapeutic agents, 128  
   therapeutic approaches, 126  
   therapeutic intravenously injected MSCs  
     BM-MSCs, 131  
     IFN- $\gamma$ , 132  
     in vivo, 132  
     pro-inflammatory/immunosuppressive  
     programs, 132

    TNF- $\alpha$ , 132  
 Inhaled corticosteroids (ICS), 145, 146  
 Innate immunity, 64–66  
 Intercellular cell adhesion molecule-1  
 (ICAM-1), 12  
 Interferon gamma (IFN- $\gamma$ ), 45, 126  
 International Society for Extracellular Vesicles  
 (ISEV), 91  
 Ischemic boundary zone (IBZ), 113

## J

Juxtacrine mechanisms, 127

## K

Keratinocyte growth factor (KGF), 127, 150

## L

Ligamentum flavum, 11  
 Lipopolysaccharides (LPS), 64, 66  
 Liver hepatic growth factor, 53

## M

Macrophage colony stimulating factor  
 (M-CSF), 65  
 Major histocompatibility complex  
 (MHC), 5, 127  
 Major histocompatibility complex class II  
 (MHCII), 147  
 Mature adipose tissue, 47  
 Mesenchymal stem cell transplantation  
 (MSCT)  
   bone marrow, 11  
   characteristics, 11  
   Crohn's disease, 15, 16  
   multiple sclerosis, 17, 18  
   preclinical studies, 12, 13  
   SLE, 14, 15  
 Mesenchymal stromal cells (MSCs), 49, 53, 56  
   biological properties, 79  
   biostatistical analysis (*see* Biostatistical  
   analysis)  
   central immunoregulatory molecules, 91  
   exosomal proteins and miRNAs, 93–98  
   GVHD setting, 79  
   HLA-G, 91  
   IBDs (*see* Inflammatory bowel  
   diseases (IBDs))  
   immune components, 37  
   immunomodulatory enzyme, 91

- Mesenchymal stromal cells (*cont.*)  
 pathways, 104  
 PGE2, 91  
 response, 82  
 Methotrexate, 4  
 Methylxanthine, 144  
 Microenvironment, 126, 127, 134  
 MicroRNA 133b (miR-133b), 113  
 Middle cerebral artery occlusion  
 (MCAO), 112, 113  
 Mixed lymphocyte reaction (MLR), 115  
 Monocyte chemoattractant peptide-1 (MCP-1),  
 65, 140, 143, 144, 150  
 MSC-derived extracellular vesicles  
 annexin A1, 93  
 anti-inflammatory cytokines, 115  
 application, 90  
 B lymphocyte function, 92  
 brain tumors, 104  
 CKD, 115  
 classification, 90  
 drug delivery system, 90  
 exosome membranes, 92  
 immune system, 116  
 intercellular short and longer-range  
 communication, 90  
 ischemic tissues, 112–114  
 KEGG pathways, 98  
 limitations, 114–115  
 macrophage function, 92  
 molecules, 90  
 neurodegenerative diseases, 114  
 paracrine activity, 90  
 pathological conditions, 116  
 prognostic biomarkers, 90  
 prokaryotic and eukaryotic cells, 90  
 PrPSc, 116  
 Reactome pathways, 99  
 T lymphocyte function, 92  
 traumatic CNS injuries, 108–112  
 web-based databases, 92  
 Multiple sclerosis (MS), 17  
 ASCs, 57  
 clinical trials, 56  
 EPI-NCSCs, 49  
 evidence-based experimental tests, 49, 50  
 HSCs, 55, 56  
 MSCs, 49, 53, 56  
 NSCs, 54, 57  
 OECs, 54  
 OPCs, 55, 56  
 stem cell therapy, 48  
 Multiple system atrophy (MSA), 12  
 Myasthenia gravis, 4, 7, 8  
 Mycophenolate mofetil (MMF), 78  
 Myelination, 55  
 Myelin inhibitory factor (MAI), 54
- N**  
 NA-chip microarray technology, 55  
 Natural killer (NK) cells, 65  
 Natural killer T (NKT) lymphocytes, 30  
 Nervous stem cells (NSCs), 54  
 Neurological niche, 54  
 Neuromyelitis optica, 8  
 Neuronal stem cells (NSCs), 47, 57  
 Nogo receptors (Ngr), 54  
 Nuclear factor kappa B (NF- $\kappa$ B), 12, 13
- O**  
 Olfactory ecto-MSCs (OE MSCs), 69  
 Olfactory ensheathing cells (OECs), 54  
 Oligodendrocyte precursor cells  
 (OPCs), 55, 56  
 Osteoblasts, 5  
 Osteoclasts, 65  
 Osteoprotegerin (OPG), 65  
 Overall response rate (ORR), 81
- P**  
 Parkinson's disease, 143  
 Perianal disease activity index (PDAI), 129  
 Perianal fistulas, 128, 130, 134  
 Permanent MCAO (pMCAO), 113  
 Peroxisome proliferator-activated receptors  
 (PPAR), 69  
 Plasminogen activator inhibitor-1 (PAI-1), 12  
 Platelet-lysate (PL), 81  
 Presence of scrapie form of the prion protein  
 (PrPSc), 116  
 Pressure of arterial oxygen (PaO<sub>2</sub>), 148  
 Progressive inflammatory sclerosis, 48  
 Pro-inflammatory (M1) macrophages, 126  
 Prostaglandin E2 (PGE2), 37, 91  
 Proteinuria, 12, 14
- R**  
 Reactive oxygen species (ROS), 140, 141, 149  
 Regulatory T cells (Tregs), 66  
 Rheumatoid arthritis (RA)  
 adipose tissue MSCs, 70  
 adult human synovium, 64  
 allogenic adipose tissue MSCs, 70  
 autologous and allogenic use, 67, 68

- B cell mechanisms, 66, 67
- DC, 66
- human umbilical cord MSC, 69
- intravenous vs. intra-articular injection, 68
- macrophages, 64
- MSC source, 71
- NK cells, 65
- non-progressive disease, 63
- osteoclasts, 65
- phenotypical variation, 70, 71
- postnatal and mesodermal tissues, 63
- priming MSCs, 68, 69
- T cell mechanisms, 66
- transplantation of MSCs, 71
- treatment and dosing regimens, 71
- Rituximab, 14
  
- S**
- Schwann cells, 54
- Senescence-associated  $\beta$ -galactosidase (SA- $\beta$ gal), 141
- Senescence associated secretory phenotype (SASP), 141–143, 146
- Short-acting muscarinic agonist (SAMA), 145
- Signal transducers and activators of transcription (STAT), 31
- Significant decrease in sirtuin 1 (SIRT1), 143
- Sjögren's syndrome, 4
- Small airway epithelial cells (SAEC), 143
- Stem cell therapy, 4, 5, 10, 18
- Stem cell transplantation, 63
  - HSCT (*see* Hematopoietic stem cell transplantation (HSCT))
  - mechanisms, 5
- Superoxide dismutase 3 (SOD3), 68
- Systemic lupus erythematosus (SLE), 9
- Systemic sclerosis (SSc), 4, 7–9
  
- T**
- T-cell receptor (TCR), 29
- Theophylline, 144
- T lymphocytes, 29
- Toll-like-receptor (TLR), 31, 68
- Toxicity, 50, 51
- Transforming growth factor beta (TGF- $\beta$ ), 126
- Transplantation, 54, 56
- Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), 12, 13, 45
  
- U**
- Ulcerative colitis (UC)
  - IBDs (*see* Inflammatory bowel diseases (IBDs))
- Umbilical cord, 6, 11, 17, 47
- Umbilical cord derived MSC (UC-MSC), 68
  
- V**
- Vascular endothelial growth factor (VEGF), 129
  
- W**
- Wharton's jelly, 11
  
- X**
- Xenotransplantation, 12